The year 2012 is coming to an end, and it’s been a big year for generic drugs. It’s the year that the most lucrative drug of all time became commoditized. It’s the year that Watson bought Actavis for $5.6 billion. And it’s the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.
The DSN PoweRx list represents nearly 80% of the total retail pharmacy business — including more than $250 billion in pharmacy sales and nearly 59,000 pharmacies. And with the rise of more consumer-centered health care, they are creating innovative programs and entering healthcare partnerships to move beyond dispensing and expand their role in the U.S. healthcare delivery system. Read more
Industry leaders talk soulful brands, doing good and operating with purpose at the third annual New General Market Summit. In this special report, DSN highlights the big ideas and best practices that emerged from the event.